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CLINICAL INVESTIGATION
PDGF and TGF-J3 contribute to the natural course of human
IgA glomerulonephritis
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EBERHARD RITZ, and RUDIGER WALDHERR
Departments of Pathology and Nephrology, Ruperto-Carola University, Heidelbe,', Germany
PDGF and TGF-p contribute to the natural course of human Ig-A
glomerulonephritis. PDGF and TGF-13 are known mediators of mesangial
cell proliferation and matrix expansion. The presence of these regulatory
factors was examined in 30 renal biopsies from patients with IgA
glomerulonephritis (IgA-GN) at the mRNA and protein level. Normal
renal tissue served as control. The mRNA expression of PDGF A/B
chains, PDGF-13R and TGF-J31 was evaluated by means of RT/PCR with
subsequent Southern blot hybridization and/or non-radiactive in situ
hybridization. In addition, PDGF-AB/BB, PDGF-13R, TGF-j3 isoforms
((31, (31+2, (32+3), the small TGF-131 latency associated peptide (TGF-131
LAP) and the extracellular matrix proteins tenascin and decorin were
analyzed by immunocytochemistry. The expression of growth factors was
correlated with light microscopic and clinical features. Compared to
normal control kidneys, an increased expression of PDGF-BB/PDGF-j3R
mRNAs and the corresponding proteins was observed in all biopsies with
IgA-GN. Up-regulation was related to the degree of glomerular prolifer-
ation and the extent of fibrosing interstitial lesions. In contrast, there was
a discordance between TGF-/31 mRNA and protein expression (evaluated
by immunocytochemistry). In all biopsies, irrespective of the stage of the
disease, abundant TGF-131 transcripts were detected, whereas TGF-131
immunoreactivity was expressed to a lesser degree and disclosed a more
variable staining pattern. In patients with significant proliferative glomer-
ular lesions and minor tubulointerstitial alterations, TGF-f31 positivity was
confined to areas of glomerular proliferation, whereas in cases with more
severe histology including sclerosing lesions TGF-31 immunoreactivity
was less prominent. The distribution and the intensity of TGF-131 LAP
staining commonly exceeded the positivity noted for TGF-p1, indicating
only limited TGF-131 activation. A decreased reactivity for tenascin
accompanied the morphological features of glomerular sclerosis. The
staining patterns and the fact that only very few inflammatory cells,
particularly CD68 positive monocytes/macrophages, were detected in
glomeruli confirm that predominantly resident glomerular cells (mesang-
ial and endothelial cells) are the major source of up-regulated growth
factor production in IgA-GN. Since the expression of PDGF-AB/BB
paralleled the severity of proliferative glomerular changes, PDGF seems
to represent a potential indicator of activity in this condition. It is
suggested that an imbalance between PDGF and TGF-J3 (by restricted
translation and/or activation) production contribute to the progressive
nature of IgA-GN.
Mesangial IgA glomerulonephritis (IgA-GN) is considered to
be the most common form of GN occurring in humans [1]. The
hallmarks of the disease are mesangial proliferation and matrix
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expansion, frequently accompanied by glomerular sclerosis, tubu-
lar atrophy and interstitial fibrosis [21.
Results of cell culture experiments together with findings
observed in animal models of mesangial proliferative GN, partic-
ularly in anti-Thy 1.1 GN, provide evidence that two growth
factors, that is, PDGF and TGF-J3s are potential mediators of
glomerular hypercellularity and matrix expansion [3—10].
An increased expression of PDGF B-chain at the protein and
mRNA level has been reported in an experimental model of
IgA-GN in mice induced by the administration of charged dextran
[9]. In human IgA-GN, an increased mesangial staining with
anti-PDGF and anti-PDGF-13R antibodies has been observed
[11—13]. Based on the elevated expression of PDGF-pR mRNA
and protein, PDGF-13R activation has been proposed as a candi-
date for the induction of glomerular and interstitial cell prolifer-
ation in IgA-GN [13]. On the other hand, an elevated glomerular
expression of TGF-f31 at the mRNA and protein level has been
reported by Yosioka et al in patients with mesangial proliferative
GN including IgA-GN [14]. Recently a relationship between the
TGF-131 protein expression and disease progression has been
suggested [15].
These findings indicate that PDGF and TGF-f3 are involved in
the pathogenesis of IgA-GN. In this study we analyzed renal
biopsies from patients with IgA-GN and different histology for the
expression of PDGF, PDGF-f3R and TGF-f3s at the protein and
mRNA level to evaluate the interplay between PDGF and TGF-13.
Furthermore, we tried to distinguish between the small latent
TGF-/31 LAP (latency associated peptide) and the active form of
TGF-/31 in biopsies with variable glomerular and tubulointerstitial
morphology.
Methods
Patients
Thirty patients with IgA-GN were included in this study (20
males, 10 females, median age 37.5 years, range 19 to 68 years).
The diagnosis was based on conventional light and immunofluo-
rescence microscopy. None of the patients received corticosteroid
or cytotoxic treatment. Systemic lupus erythematosus, Henoch-
SchOnlein purpura, and hepatic diseases were excluded by de-
tailed clinical history, examination and laboratory tests. Patients
have been followed at the Department of Nephrology, University
of Heidelberg, and subjected to renal biopsy between December
1987 and December 1991.
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Table 1. Histological and clinical data of patients at time of renal biopsy
Glomerular Duration of
Age years! Crescents obsolescence symptoms
No. sex % % years
Serum Urinary
creatinine protein
mg!dI g/24 hr
Urinary
eiythrocytes
E/mm3
MGA
1 39/M — — 15 1.2 0.2 56,000
2 21/F — — 6 0.8 0.6 25,000
3 36/M — — 16 0.9 0.2 gross hematuria
4 27/Me — — 6/12 1.2 0.3 317,000
5 20/Ms — — 3/12 0.9 0.4 gross hematuria
6 31/Me — 10 10 0.9 0.3 24,000
7 29/Ms — 12 5 1.0 0.2 162,000
MGN
8 19/M — — 10 0.8 0.4 45,000
9 34/M — — 6/12 0.9 0.5 gross hematuria
10 30/M — 17 3 0.6 0.5 10,000
11 28/M — — unknown 0.9 0.3 gross hematuria
12 49/Ms — — unknown 1.0 2.4 50,000
CrGN
13 43/P 17 — 0.9 4.1 95,000
14 28/P 22 22 unknown 0.9 4.9 100,000
15 39/M 67 — 3/12 1.5 10.8 10,000
16 60/M 25 — 2/12 2.4 3.0 20,000
17 23/P 78 22 unknown 1.7 2.0 100,000
ScGN
18 54/P — 35 10 1.7 2.7 100,000
19 42/W — 67 13 1.6 2.1 117,000
20 32!M — 54 5 1.6 7.0 375,000
21 31/Ms — 42 1 1.5 1.7 100,000
22 40/P — 43 33 1.8 1.2 40,000
23 68/Me — 56 1 1.9 3.5 260,000
24 49/Me — 56 15 2.0 4.1 gross hematuria
25 40/P — 44 1/12 2.2 2.3 113,000
26 36/P — 78 2/12 2.7 2.0 400,000
27 57/M — 60 unknown 1.6 1.8 10,000
28 39/M — 38 10 2.7 11.4 48,000
29 45/M — 75 6 3.0 2.0 15,000
30 37/M — 78 unknown 6.4 3.2 110,000
Abbreviations are: MGA, minimal glomerular abnormalities; MGN, mesangial proliferative glomerulonephritis; CrGN, mesangial proliferative
glomerulonephritis with segmental crescents; ScGN, sclerosing glomerulonephrititis.
a Patients/biopsies in whom in situ hybridization studies were performed.
Morphologically, the patients presented with different grades of
mesangial expansion/proliferation and/or sclerosis and a variable
extent of tubulointerstital lesions. Four categories of histological
alterations could be distinguished:
(1) Minimal glomerular abnormalities (MGA) with no or only
minor tubulointerstitial alterations including focal tubular atrophy
with peritubular fibrosis and scattered mononuclear infiltrates,
seven cases;
(2) Diffuse mild to moderate mesangial proliferative GN
(MGN) with no or only minor tubulointerstitial lesions, five cases;
According to the WHO classification of glomerular diseases,
mesangial proliferation was defined as diffuse increase in mesang-
ial cells and matrix with more than three nuclei per mesangial
area.
(3) Mesangial proliferative GN with segmental adhesions!
crescents (CrGN) present in up to 78% of glomeruli (Table 1)
associated with marked tubular atrophy, peritubular fibrosis and
mononuclear infiltrates, five cases;
(4) MGN with pronounced glomerular sclerosis (global or
segmental) (sclerosing GN, ScGN), present in more than 30% of
glomeruli and advanced tubulointerstitial lesions, 13 cases.
Morphological, clinical and laboratory data are summarized in
Table 1. Clinically, all patients exhibited hematuria (microscopic
or macroscopic) with a variable degree of proteinuria and normal
or impaired renal function.
Renal biopsies
Tissue preparation for conventional immunofluorescence mi-
croscopy, immunocytochemistry and in situ hybridization was
performed as described previously [16}. The immunocytochemical
studies were conducted on renal specimens from all patients.
Since diagnostic immunofluorescence and the immunocytochem-
ical studies were done on one single needle biopsy specimen,
adequate remaining tissue for in situ hybridization (and/or RNA
isolation) was available from 17 patients only.
Immunocytochemical technique
The following primary antibodies were applied in this study: a
murine monoclonal antibody to TGF-pl (M 700020, Antigenix
America, Franklin Square, NY, USA), an anti-TGFf31 + 2
polyclonal antibody, raised in rabbits (Rb # 5, Celtrix, Palo Alto,
CA, USA), a murine monoclonal anti-TGF/32 + f33 antibody (GF
16, Oncogene Science, Unlondale, NY, USA), a goat polyclonal
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antibody to TGF-f31 LAP (AB-246-PB, R & D Systems, Minne-
apolis, MN, USA), a polyclonal antibody to PDFG-AB het-
erodimer raised in goat (BDA 16, R & D Systems), a rabbit
polyclonal antibody to PDGF-BB (ZP-215, Genzyme, Boston,
MA, USA), a murine monoclonal antibody to PDGF receptor
/3-subunit (PDGF-13R) (1263-00, Genzyme), rabbit polyclonal
antibodies to tenascin and decorin (provided by Dr. D. Schuppan,
Department of Clinical Medicine, Free University of Berlin,
Germany), and a murine monoclonal antibody to CD68 (EMB1 1,
M718, DAKO A/S, Glostrup, Denmark). With the exception of
anti-TGF-/31 LAP, aceton fixed (at 4°C) cryostat sections were
used. For TGF-/31 LAP detection cryostat sections were fixed in
3% buffered paraformaldehyde. The immunostaining procedure
was performed using the APAAP (alkaline phosphatase anti-
alkaline phosphatase) method as described previously [161. In the
case of anti-TGF-f31 LAP, incubation with the primaly antibody
was performed in the presence of 0.3% Triton X-100.
Normal human kidney tissue obtained from patients with
tumour nephrectomies (N = 10) served as controls. Control
experiments were carried out by omitting the incubation with the
primary antibodies and by substitution of the primary antibody
with a non-immune murine serum or normal rabbit/goat serum.
The numbers of immunoreactive cells in biopsy specimens were
scored separately in glomeruli and in the interstium according to
the following scheme: + - single positive cells in a focal distribu-
tion, + + - diffusely scattered positive cells, + + + - numerous
positive cells, frequently in clusters.
In situ hybridization
Probe preparation. To generate riboprobes, cDNA fragments
were subcloned into pGEM transcription vectors between SP6
and T7 promoters (Promega Biotech, Madison, WI, USA). A 918
bp PstI-NcoI fragment of human PDGF B-chain eDNA (a gift of
Dr. Ch. Betsholtz, University of Uppsala, Sweden) [17], contain-
ing full coding region, was subcloned into pGEM-5zf( +). A 897
bp SmaI-PstI fragment of human PDGF-/3R eDNA (a gift of Dr.
Ch. Betsholtz) [18] was subcloned into pGEM-4z. A 457 bp
BalI-NcoI fragment of TGF-/31 eDNA (obtained from ATCC, cat.
# 59954, Rockville, MD, USA) [19] containing sequence coding
for the TGF-/31 mature protein was subeloned into the pGEM-3z
vector. The templates were linearized with the appropriate re-
striction enzymes. Afterwards, labeled anti-sense and sense cRNA
probes were generated using SP6 or T7 polymerases and digoxi-
genin-labeled uridine-triphosphate (DIG-UTP) as substrate ac-
cording to the manufacturer's instructions (DIG RNA labeling
kit, Boehringer-Mannheim, Mannheim, Germany) [20].
Hybridization. Preceeding hybridization, tissue was pretreated
for 30 minutes with 0.1% Triton X-100 in PBS (phosphate
buffered saline), pH 7.2. Afterwards slides were washed in PBS,
fixed in 3% buffered paraformaldehyde for 15 minutes, rinsed in
PBS, immersed in 0.1 M triethanolamine (pH 8.0) with the
addition of 0.4% acetic anhydride for 10 minutes, washed in PBS
and finally dehydrated in graded alcohol. DIG-labeled cRNA was
denatured for five minutes in 10 mivi Tris, 5 mrvi EDTA, at 95°C.
Probes were chilled on ice and added to the hybridization mixture
that contained 50% formamide, 1 X Denhardt's solution (0.02%
polyvinylpyrrolidone, 0.02% Ficoll type 400, 0.02% BSA), 10%
dextran sulfate, 500 j.g/m1 sheared salmon sperm DNA, 500 Lg/ml
yeast tRNA, 10 ifiM Tris pH 7.5, 1 mivi EDTA, and 50 mM DTT
(dithiothreitole). Sections were hybridized overnight in a humid
chamber. Afterwards, slides were washed two times in 1 x SSC
(sodium saline citrate, 1 X SSC = 0.15 M NaC1 + 0.015 M sodium
citrate), 5°C below the hybridization temperature and two times in
1 x SSC at the hybridization temperature. The last washing step
consisted of 1 X SSC for one hour at room temperature.
Subsequently, colorimetric detection of mRNA was accom-
plished with the DIG-Nonradioactive Nucleic Acid Detection Kit
according to the manufacturer's instructions (Boehringer-Mann-
heim) with some modifications. Sections were incubated for 30
minutes in buffer 1 (100 mrvi Tris-HCI, 150 mivi NaCl; pH 7.5)
containing 1% normal sheep serum (NSS) and 0.1% Triton
X-100. Then 100 pA of anti-digoxigenin antibody conjugated to
alkaline phosphatase (1:800 dilution) in buffer 1 with the addition
of 2% NSS was applied on the slides and incubated for three
hours at room temperature. The sections were rinsed briefly in
buffer 1 and buffer 2 (100 mivi Tris-HCI, 100 mivi NaC1, 50 mM
MgCI2, pH 9.5) and immersed into the color solution. The
developing reaction was carried out at room temperature in the
dark, overnight. The reaction was stopped in buffer 3 (10 mM
Tris-HC1, 1 mivi EDTA; pH 8.0) and slides were dehydrated in
graded alcohol. The coverslips were placed on the sections with
glycerin-gelatin.
Negative controls consisted of matched serial sections hybrid-
ized with sense probes, sections hybridized with unlabeled anti-
sense probes, and sections pretreated with 200 .tg/ml RNAse A
for one hour (Sigma) before hybridization with the corresponding
anti-sense probe.
The expression of PDGF B-chain, PDGF-/3R and TGF-f31 in
the samples was scored by comparing the localization and the
number of positive cells with the expression in normal renal tissue
(N = 10) as described for the immunocytochemical procedure.
Reverse transcription/polymerase chain reaction (RT/PCR)
Total RNA isolation, reverse transcription and PCR were
performed as described elsewhere [16]. Due to the small amounts
of tissue left, only 0.2 ig of total RNA was transcribed into
cDNAs for TGF-f31, PDGF A-chain, PDGF B-chain, and PDGF-
/3R, respectively. Each PCR cycle comprised a denaturation step
of one minute at 95°C followed by a one minute annealing step at
58°C for the PDGF B-chain and the PDGF-f3R, a 59°C annealing
step for TGF-f31, and a 63°C annealing step for the PDGF
A-chain. An extension step at 72°C for two minutes followed for
all PCR reactions. The PCR amplification consisted of 40 cycles.
Taq polymerase was added during the first annealing steps under
hot start conditions.
The PDGF B-chain primers amplified a fragment of 217 bp
[21], and the PDGF-f3R, PDGF A-chain and TGF-/31 primers
amplified fragments of 228 bp [21], 301 bp [21] and 224 bp [22],
respectively (Table 2). The resulting fragments were electropho-
resed on a 2% agarose-gel in TBE-buffer. Southern blots were
performed to confirm the specificity of the PCR-positive bands.
The electrophoresed PCR-products were blot-transferred onto a
nylon membrane (Nytran-N, Schleicher & Schüll, Dassel, Ger-
many) and the filters were baked at 80°C for two hours. The filters
were prehybridized in 10 ml of lOX Denhardt's solution in 6 X
SSC, 500 Wml sheared salmon sperm DNA for two hours at
room temperature, and then hybridized overnight in the same
solution containing 32P-labeled oligonucleotides (Table 2) labeled
at 5'-end using polynucleotide kinase (New England Biolabs,
Beverly, MA, USA). Filters were then washed twice in 6 X SSC at
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Table 2. 5' and 3'oligonucleotide primers of PDGF A-chain, PDGF B-chain, PDGF-j3R and TGF-pl and corresponding internal
oligonucleotide probes
5'-Primer 3'-Primer
Size of the PCR
product (bp) Internal oligonucleotide probes
PDGF-A 5'-CCT GCC CAT TCG GAG 5'-rrG GCC ACC TrG ACG CTG 301 5-ACT TGA CAC TGC TCG TGT
GAA GAG-3 CG-3' TGC-3'
PDGF-B 5'-GAA GGA GCC TGG GTT s'-m CTC ACC TGG ACA GGT 217 5'-GTF GCA GCA GCC GGA GCA
CCC T-3' CG-3' GCG CTG-3'
PDGF-3R 5'-GAC CAC CCA GCC ATC 5'-GAG GAG GTG TUG ACT TCA 228 5'-GAC ACC AGC TCC GTC
CTTC-3' TrC-3' CTC-3'
TGF-f31 5'-GAG CCT GAG GCC GAC 5'-CTG GTA CAG CTC CAC GTG 224 5'-GAC AAG YI7C AAG CAG AGT
TAC TA-3' CT-3' AC-3'
room temperature and then in 6 X SSC with 1% SDS at 60°C, and
autoradiographed with intensifying screens at —70°C. Controls
comprised RNA isolation (N = 3) from normal renal tissue
followed by the procedure described above.
Results
Immunocytochemistty
TGF-13. A weak positivity was observed in glomeruli of normal
kidney in endothelial, mesangial, and capsular cells with all
TGF-13 antibodies applied (Fig. 1). A comparable TGF-f3 expres-
sion was present in most glomeruli of biopsies from patients with
minor glomerular abnormalities. Glomeruli with segmental me-
sangial hypercellularity and cases with diffuse mesangial alter-
ations and no or only mild accompanying tubulointerstitial lesions
disclosed, however, a marked glomerular positivity for TGF-J31,
predominantly in the mesangium (Fig. 2). Thus, an increased
expression of TGF-f31 was observed in areas of mesangial prolif-
eration. Glomerular expression of TGF-131 was decreased or
completely negative in obsolescent glomeruli and in segmental
sclerosing lesions, particularly in patients with an advanced stage
of the disease. Comparable reaction patterns were observed with
the monoclonal antibody to TGF-132+3.
TGF-J31 positive cells were scattered throughout the intersti-
tium in cases with MGA and mild proliferative GN. Numerous
positive cells were seen in cases with advanced stages of the
disease where dense mononuclear infiltrates and marked intersti-
tial fibrosis were present. In these biopsies some positivity in
tubular epithelial cells, particularly in distal tubular cells, was also
observed when a polyclonal rabbit anti-TGF/31 + 2 antibody was
used. No tubular staining, however, was seen with the monoclonal
anti-TGF-f31 antibody.
TGF-f31 LAP expression in the normal kidney (Fig. 1) was more
widespread and more intense than that observed with the anti-
TGF-31 monoclonal antibody. It was particularly noted in gb-
meruli (endothelial and mesangial cells, some podocytes, cells of
Bowman's capsule), in vessel walls, interstitial cells and in distal
tubular epithelial cells. The pattern of TGF-/31 LAP positivity in
glomeruli from patients with MGA approximately corresponded
to that observed in normal kidney. In biopsy specimens from
patients with MGN, CrGN and ScGN, a variable immunoreactiv-
ity of TGF-/31 LAP was observed, particularly among glomeruli
with different histological lesions in the same section. When
comparing the expression of TGF-j31 LAP (Fig. 3) and of TGF-f31
(Fig. 4) in sequential sections, it became obvious that, in at least
some glomeruli TGF-131 LAP positivity was accompanied by a
significantly less positive and sometimes even negative reaction
for TGF-/31. Furthermore, in some areas with strong TGF-pl
positivity staining intensity for TGF-f31 LAP was reduced. In
patients with CrGN and ScGN, TGF-131 LAP was additionally
present in mononuclear interstitial infiltrates and in some distal
tubular epithelial cells.
Decorin. No significant glomerular positivity for decorin was
found in the normal kidney and in the biopsy specimens exam-
ined, irrespective of the stage of the disease. In contrast, the
interstitial expression of decorin varied. In patients with MGA,
staining was prominent in the interstitial matrix, particularly
surrounding interstitial cells (Fig. 5). This pattern of expression
was principally comparable to that observed in the normal kidney.
In patients with marked proliferative glomerular changes and
severe interstitial infiltration, the interstitial staining for decorin
was focally diminished or even disappeared, a positive reaction
being mainly confined to areas of interstitial fibrosis.
Tenascin. The immunoreactivity for tenascin in biopsies with
MGA corresponded to that observed in normal kidney. However,
in cases with mild to moderate gbomerular proliferation accom-
panied by an increased staining with the anti-TGF-/31 monocbonal
antibody the expression of tenascin was slightly increased (Fig. 6).
In patients with CrGN, and particularly ScGN, the expression of
tenascin was reduced, reflecting the pattern of TGF-131 immuno-
reactivity. The interstitial positivity for tenascin was similar to that
observed for decorin.
PDGF. Similar to TGF-13s, a very faint staining for PDGF-
AB/BB and PDGF-/3R was observed in the normal kidney,
particularly in the mesangium and the interstitium. In patients
with IgA-GN increased glomerular immunoreactivity for
PDGF-/3R and PDGF-AB/BB was present in areas of mesangial
proliferation, although it was also visible in gbomerular endothe-
hal cells and capsular cells. The strongest expression of both
proteins was noted in glomeruli with segmental crescentic lesions
(Figs. 7 and 8). Gbomerular positivity diminished with the devel-
opment of sclerosis, while concomitantly an increment in the
tubulointerstitial immunoreactivity could be observed. Apart from
areas of interstitial fibrosis and mononuclear infiltrates where the
positivity for PDGF-AB/BB was particularly strong, some tubular
epithehial cells, namely distal tubular cells, disclosed a moderate
positive reaction for PDGF and its receptor (Fig. 8).
Macrophages. Single CD68 positive cells were found in glomer-
uli independent on the rate of mesangial expansion/proliferation
or the presence of sclerotic lesions. Numerous CD68 positive cells
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Fig. 1. Top left. TGF-f31 LAP immunoreactivity in a normal glomerulus (control). A positive reaction is observed in endothelial cells, mesangial areas,
some podocytes and in capsular epithelial cells. Furthermore, interstitial cells and endothelial and smooth muscle cells of arterioles are positive (X250).
Fig. 2. Top right. TGF-!31 immunoreactivily in a patient with mesangial proliferative GN and mild interstitial lesions. TGF-131 is positive in areas of
mesangial proliferation, in some endothelial cells, in capsular epithelial cells and in interstitial infiltrating cells (X250).
Fig. 3 and 4. Second left, right. TGF-31 LAP (Fig. 3) and TGF-f31 (Fig. 4) immunoreactivity in a patient with mesangialproliferative GN and segmental
crescents. The Figures demonstrate the same glomerulus on sequential sections. TGF-131 LAP is strongly positive in almost all glomerular cells, whereas
TGF-131 immunoreactivity is less prominent or even negative in segmental areas (X250).
Fig. 5. Third left. Decorin expression in a biopsy with moderate mesangial proliferative GN. A positive reaction is limited to the interstitium (X250).
Fig. 6. Third right. Tenascin positivity in mesangial proliferative GN. Compared to controls a slightly increased immunoreactivity is observed in the
glomerulus (mesangial cells, capsular epithelial cells) and in the interstitium (X250).
Fig. 7. Bottom left. Biopsy from a patient with mesangial proliferative GN and segmental crescents. PDGF-13R protein is expressed in mesangial areas, in
crescentic cells, and in periglomerular infiltrating cells (X250).
Fig. 8. Bottom right. PDGF-ABIBB immunoreactivily in a biopsy specimen from a patient with mesangial-proliferative GN. The positive reaction is
confined to nearly all glomerular cells. Distal tubular epithelial cells and cells in areas of periglomerular fibrosis are also positive for this growth factor
(x250).
Fig. 9. Top left. In situ hybridization using digoxigenin-labeled PDGF B-chain antisense riboprobe of a biopsy from a patient with mesangialproliferative GN
with mild interstitial lesions. PDGF B-chain transcripts are present in mesangial cells, capsular epithelial cells and interstitial cells (X250).
Fig. 10. Top right. In situ hybridization with a PDGF B-chain antisense riboprobe in a biopsy specimen from patient with mesangialproliferative GN and
segmental crescents. Apart from mesangial cells, endothelial cells and capsular epithelial cells disclose transcripts for PDGF B-chain (X250).
Fig. 11. Bottom left. PDGF-j3R mRNA in a glomerulus from a patient with mesangial proliferative GN. Transcripts are primarily observed in mesangial
and capsular cells but also in interstitial and distal tubular epithelial cells (X250).
Fig. 12. Bottom right. TGF-J31 mRNA in a biopsy from patient with mesangial proliferative GN. Numerous TGF-31 positive cells in a glomerulus with
marked proliferative lesions. TGF-pl transcripts are also present in distal tubular epithelial cells and in periglomerular infiltrating cells (x250).
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were seen in the interstium in cases with marked tubulointerstitial
lesions.
In situ hybridization
Small amounts of mRNA transcripts for PDGF B-chain,
PDGF-f3R and TGF-/31 were detected in normal kidney. They
were predominantly localized in mesangial areas, cells of the
Bowman's capsule and in the interstitium.
An increased expression of mRNAs for PDGF B-chain,
PDGF-/3R and TGF-f31 was observed in all biopsies examined
(Fig. 14). In patients with minor glomerular abnormalities tran-
scripts were increased in mesangial areas of some glomeruli and
frequently observed in a segmental distribution. Kidney biopsies
from patients with mild diffuse proliferative lesions disclosed an
increased amount of mRNAs in the majority of glomeruli in
mesangial areas (Fig. 9 and 11). In addition, PDGF B-chain and
TGF-pl mRNAs were observed in some tubular epithelial cells,
particularly of distal tubules.
A marked increase in mRNAs expression was observed in
samples from patients with diffuse mesangial proliferative GN
associated with segmental crescents (Fig. 10). Positivity was not
confined to mesangial areas but was also seen in glomerular
endothelial cells, parietal epithelial cells and cells of crescents.
Periglomerular and interstitial infiltrating cells as well as distal
tubular epithelial cells also disclosed positive signals.
In chronic sclerosing GN, the majority of TGF-/31, PDGF
B-chain and PDGF-/3R transcripts were localized in the tubulo-
interstitial compartment. Apart from tubules, an expression of
these mRNAs was particularly noted in areas of interstitial fibrosis
and interstitial infiltration.
Both PDGF B-chain/PDGF-f3R mRNAs and the respective
proteins were usually observed in the same location. Of particular
interest was the comparison between TGF-f31 mRNA expression
and the positivity for TGF-j31 and TGF-/31 LAP proteins as
evaluated by immunocytochemistry (Figs. 12 and 13). Increased
TGF-pl LAP reactivity was noted in all biopsy samples examined
irrespective of the stage of the disease. The distribution and the
staining intensity of TGF-f31 LAP protein frequently exceeded the
positivity for TGF-J31 mRNA and TGF-f31 protein. In some
glomeruli or glomerular segments, particularly in cases with
advanced glomerular alterations, a marked immunoreactivity for
TGF-131 LAP protein was observed, whereas no significantly
increased TGF-f31 mRNA could be detected. In contrast, both
TGF-pl LAP and TGF-131 mRNA were usually present in
interstitial infiltrates. The results of TGF-f31 detection at the
protein and mRNA level are summarized in Figure 14.
Clinicopathological correlations
In patients with mild to moderate mesangial proliferation
(MGA, MGN; Fig. 14) and an increased expression of TGF-f31,
PDGF and PDGF-/3R, the predominant clinical feature was
erythrocyturia with no or only mild proteinuria. In contrast,
patients with marked glomerular proliferation and crescents
characterized by a prepondarance of PDGF-AB/BB and
PDGF-13R presented not only erythrocyturia but also significant
proteinuria, sometimes even in the nephrotic range.
Reverse transcription/polymerase chain reaction (RT/PCR)
Figure 13 presents the results of the PDGF-/3R (Fig. 13A) and
PDGF A-chain (Fig. 13B) mRNA expression in renal biopsies
analyzed by RT/PCR.
No PDGF-pR transcripts were seen in three cases (patients 23,
24, 25). In the remaining 13 cases the specificity of the RT/PCR
products could be confirmed by means of Southern blot hybrid-
ization using the internal oligonucleotide PDGF-pR probe.
PDGF A-chain transcripts were detected in 10 out of 12 cases.
After RT/PCR amplification, using primers specific for PDGF
B-chain and TGF-f31, fragments of the expected length (217 bp
and 228 bp, respectively) were detected in all 12 cases examined.
The specificity of the PCR products was confirmed by Southern
blotting with PDGF B-chain and TGF-131 oligonucleotide probes
(data not shown).
Discussion
Human IgA-GN usually has a slow rate of loss of renal function
[23]. Despite considerable work to elucidate the pathogenesis of
this disease, the precise mechanisms leading to mesangial prolif-
eration/matrix expansion and subsequent glomerular sclerosis
with accompanying interstitial fibrosis remains unknown.
Our results document that both PDGF and TGF-f3 are involved
in the evolution of mesangial IgA-GN. Although a role for these
growth factors in the pathogenesis of IgA-GN has been proposed
by others [11—15], there has never been an attempt to simulta-
neously analyze the expression of PDGF and TGF-f3 at the
mRNA and protein levels in human IgA-GN. We demonstrate
that PDGF, PDGF-/3R and TGF-J3 proteins are expressed in the
glomeruli and the tubulointerstitial compartment. Using reverse
transcription with subsequent cDNA amplification and Southern
blot hybridization we show the presence of mRNAs for PDGF
B-chain, PDGF A-chain, PDGF-13R and TGF-131. Results of in
situ hybridization confirm these findings. The most important
advantage of in situ hybridization using cRNA anti-sense probes
was the ability to demonstrate the local up-regulation of growth
factors in IgA-GN. Results of immunocytochemistry suggested a
focal increase in PDGF-AB/BB and TGF-J3 expression in our
biopsy specimens. Findings of in situ hybridization definitely
permitted this conclusion. The failure to detect PDGF A-chain
and PDGF-j3R RNA transcripts in some of the remaining tissue
samples using RT/PCR can be explained by the local distribution
of growth factor expression, or, more likely, by RNA loss during
the isolation procedure. Furthermore, variations in TGF-pl
mRNA/protein and TGF-pl LAP protein expression allow some
hypotheses concerning mechanisms involved in the regulation of
TGF-/3 protein synthesis.
One important question that requires elucidation is the cellular
source of growth factors produced within glomeruli and the
tubulointerstitial compartment. In glomeruli, cells presenting
PDGF-13R/PDGF B-chain and TGF-f31 message and protein
seem to belong to the intrinsic population of glomerular cells.
Cells of the macrophage lineage could only sporadically be
detected within glomerular tufts. According to previous studies 3,
5, 6, 8], mesangial cells are able to both produce and respond to
PDGF and TGF-J31. For both growth factors an autocrine mode
of action has been proven in cell culture experiments [5, 8]. The
positive signal for these factors was so strong, however, particu-
larly in patients with proliferative lesions, that it is rather unlikely
that mesangial cells are the sole cellular source. Our experiments
suggest that in addition to mesangial cells, glomerular endothelial
and capsular epithelial cells are capable of producing PDGF and
TGF-/31. With respect to TGF-/3, glomerular endothelial and
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Fig. 13. Results of PDGF A-chain (A) and
PDGF-13R (B) mRNA expression in renal
biopsies analyzed by RTIPCR with subsequent
Southern blot hybridization. The upper part of
the Figure presents ethidium bromide staining
of the PCR products separated in 2% agarose
gel. The expected size of PCR fragments is
indicated on the left in base pairs (bp). The last
three lanes represent mRNA analysis of normal
renal tissue. The number above slots indicate
patients mentioned in Table 1. The lower part
of the Figure shows the results of Southern blot
hybridization with PDGF A-chain and PDGF-
R internal oligonucleotide probes.
epithelial cells have been reported to possess receptors for this
cytokine [6]. Immunocytochemical studies on the PDGF-/3R
subunit expression in normal human kidney have documented
PDGF-f3R in mesangial, capsular epithelial and interstitial cells
[24]. Furthermore, it has been shown that PDGF-/3R expression
can be modulated by culture conditions, such as by growing cells
in monolayer configuration versus three-dimensional type I colla-
gen gels [25]. Neoexpression of PDGF-13R protein and its mRNA
has been observed in several inflammatory conditions, particularly
in vessel walls in healing wounds [26] and the rheumatoid synovia
[27]. Furthermore, the presence of PDGF-/3R on rabbit retinal
endothelial cells has recently been reported [28]. By analogy, it is
possible that PDGF-f3R is induced on glomerular endothelial cells
by inflammatory signals so that endothelial cells participate in the
proliferative process. This assumption is sustained in some of our
biopsies examined even if we must admit that it is difficult to
differentiate betwen mesangial and endothelial cells on cryostat
sections.
It is commonly assumed that visceral epithelial cells are the type
of glomerular cells which are most specialized with respect to
function and differentiation [29, 30]. Glomerular visceral epithe-
hal cells have been shown to produce PDGF-BB, although no
PDGF-13R could be detected [31]. These cells also produce
heparan sulfate [32], an important constituent of the glomerular
matrix. Heparan sulfate has been shown to suppress PDGF-BB
production [33]. Thus, cell-matrix interactions may be an impor-
tant factor in the regulation of proliferative responses in glomer-
uli. The presence of PDGF-J3R on capsular epithelial cells and
their ability to produce PDGF-BB suggest that this growth factor
is involved in epithelial cell proliferation and crescent formation
in IgA-GN.
Apart from intrinsic glomerular cells and cells of the monocyte!
macrophage lineage other blood-derived cells, that is, lympho-
cytes could be responsible for the production of growth factors.
Two recent studies showed an increase in cells with T helper!
inducer features in the blood of patients with IgA-GN [34]. The
ability of such cells to produce TGF-131 [15] may support this
assumption. According to our experience, however, glomerular
accumulation of T cells is not a prominent finding in IgA-GN.
Whatever the source of growth factors produced in glomeruhi,
our in situ hybridization results suggest a relationship between the
production of these growth factors and the severity of the
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Fig. 14. Semiquantitative evaluation of TGF-131
mRNA, TGF-131 LAP, TGF-131 protein, PDFG1 B-chain mRNA, PDGF-AB/BB protein, PDGF-
R mRNA and PDGF-f3R protein expression in
renal biopsies from patients with IgA-GN. The
Not present score relates to the predominant glomerularlesion(s) enabling the classification into one of
the four histological categories: (Lx)0 MGAlminor glomerular abnormalities; (0)
TGF-131 mRNA TGF-131 LAP TGF-I1 PDGF-13R and PDGF-1R and MGN/mesangial proliferative GN; (U) CrGNI
protein protein PDGF B-chain PDGF AB/BB mesangial proliferative GN with crescents; (S)
mRNA protein ScGN/sclerosing GN.
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histological lesions. In patients with minor glomerular abnormal-
ities and diffuse mesangial proliferative lesions in glomeruli but
without or with only mild tubulointerstitial alterations, an increase
in growth factor expression can be limited to some glomeruli, or
restricted to some glomerular segments. The amount of message
for PDGF-13R!PDGF B-chain and TGF-t31 in tubules and in the
interstitium is related to the number of RNA transcripts in the
adjacent glomeruli. It is particularly visible in patients with
proliferative lesions in glomeruli and minor tubulointerstitial
alterations. When comparing the expression of mRNA evaluated
by in situ hybridization and of protein determined by immunocy-
tochemistiy, major differences are obvious between PDGF and
TGF-f3. Whereas the number of transcripts for PDGF B-chain!
PDGF-j3R parallels the expression of the respective proteins, an
increased amount of TGF-131 mRNA transcripts in comparison to
TGF-f31 protein is noted in glomeruli. It is unlikely that this
discrepancy is due to a lack of antibody specificity or affinity since
we observed particularly strong staining reactions in other condi-
tions, that is, crescentic and necrotizing GN or acute transplant
rejection. An excess of TGF-/31 LAP in comparison to TGF-pl
protein positivity suggests local translational and post-transla-
tional modifications in the TGF-/31 activation process.
Growth factors produced by glomeruli may reach tubules via
the glomerular ultrafiltrate or via the bloodstream in peritubular
capillaries. In addition, these factors may be produced by tubular
epithelial cells themselves and by interstitial cells. Cell culture
experiments documented that proximal tubular epithelial are
unresponsive to PDGF [35]. In agreement with these observations
we did not observe PDGF-13R and PDGF B-chain transcripts in
proximal tubules. In patients with marked tubulointerstitial alter-
ations, however, PDGF B-chain and TGF-f31 transcripts were
noted in distal tubules. Intriguingly, no or only minor immunocy-
tochemical staining for TGF-pl was observed in distal tubular
epithelial cells. Since an abundance of TGF-131 LAP could be
detected in this compartment, a particular mode of TGF-13
activation seems to operate in distal tubules. In contrast, both
PDGF B-chain mRNA and protein were present in distal tubular
epithelial cells. In patients with marked tubulointerstitial alter-
ations, the majority of interstitial fibroblasts were positive for
PDGF-AB!BB and PDGF-f3R and expressed the corresponding
mRNAs, indicating the prominent role of PDGF in the develop-
ment of interstitial fibrosis.
To date, based on the results of experimental studies with
anti-Thy 1.1 model of GN, it has been claimed that TGF-131 is
involved in the development of glomerular sclerosis and intersti-
tial fibrosis [4, 7, 15, 36]. However, if one keeps in mind that
following the acute phase of anti-Thy 1.1 GN mesangial injury is
completely resolved [37], another interpretation of the action of
this growth factor would be that it is involved in the restitution of
glomerular lesions after acute injury. Such a point of view may be
supported by recent experiments of Barnes and Abboud in the
Habu snake venom-induced GN [38]. This model is characterized
by an acute phase of mesangial proliferation. The detection of
PDGF protein and mRNA is temporally related to the onset and
the abatement of mesangial proliferation. The expression of
TGF-f3 follows after the PDGF response. The course of events
observed in both types of acute experimental GN indicates that a
sequential transient upregulation of PDGF and TGF-13 occurs
after an acute damage to glomeruli. It is thus part and parcel of
restorative processes which lead to the resolution of glomerular
inflammation.
Against this background, the simultaneous expression of both
growth factors in IgA-GN is remarkable. Interestingly, when the
glomerular changes are accompanied not only by an increased
PDGF-AB!BB and PDGF-/3R expression but also by a significant
TGF-/31 immunoreactivity, the clinical symptoms of the disease
are less pronounced. The observation of abundant PDGF mes-
sage and PDGF protein in renal biopsies of patients with more
severe histological lesions indicates that this growth factor is an
indicator of disease activity. This point of view is in agreement
with the results of studies in experimental models of IgA-GN in
mice induced by the administration of charged dextrans [11]. In
these experiments the increased expression of PDGF B-chain
within the mesangium and in the interstitium correlated with the
severity of the proliferative response and the degree of protein-
uria and erythrocyturia. In another form of experimental GN
induced by repeated injections of BSA in rats, sustained expres-
sion of PDGF B-chain mRNA using RT!PCR has been shown
[39]. Furthermore, infusion of PDGF-BB [40] or transfection of
the PDGF B-chain gene [411 indicate that PDGF BB is not only
able to cause a proliferative response in glomeruli but also to
induce pronounced matrix expansion. With respect to PDGF-13R,
our results are in full agreement with those obtained by Gesualdo
et al [13] in patients with proliferative GN including IgA-GN.
The acute models of GN suggest that TGF-13 may have a role in
limiting the proliferative response of glomerular cells. The finding
of increased TGF-13 protein expression in patients with mild to
moderate proliferative lesions in glomeruli and only minute
clinical symptoms may indicate the participation of TGF-p in the
limitation of glomerular lesions. Such an interpretation is favored
by recent transfection experiments of Kitamura et al [42]. When
mesangial cells are transfected with cDNA for TGF-f31 and
subsequently infused into nephritic glomeruli, a suppressive effect
on glomerular proliferation is observed. This idea is further
supported by the expression of tenascin in our biopsy specimens.
Tenascin has been reported to reflect the action of TGF-j3 [43]
and to be an important extracellular component of the glomerular
microenvironment [44]. Knockout mice without the tenascin gene
developed more severe lesions in glomeruli when an acute GN
was induced [451. Thus, the pattern of a relatively low tenascin
expression in biopsies with advanced glomerular lesions may
reflect a failure in TGF-J31 translation and post-translational
activation. With respect to decorin, we detected no expression of
this extracellular matrix protein in glomeruli of normal kidney or
patients with IgA-GN. Similar results have been reported by
Yoshioka et al [14].
We conclude that both PDGF and TGF-13 genes are transcribed
and translated in the evolution of human IgA-GN. Their up-
regulation and localization in the glomerulus and in the tubulo-
interstitial compartment within the various cell types allows an
intensive cross-talk between these cells. We provide evidence that
PDGF is particularly involved in the progression of the disease,
particularly in the development of pronounced proliferative gb-
merular changes and fibrotic interstitial lesions. Differences in the
expression of TGF-f3 in renal biopsies with mild!moderate and
severe histological features suggest that this factor is not primarily
involved in the progression but in the limitation of the extent of
the morphological lesions. Even if this hypothesis cannot be
proven in the present study, the elucidation of the mechanisms
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responsible for TGF-13 translation and/or post-translational acti-
vation and leading to a local imbalance between PDGF and TGF
is of major importance.
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